Drug intelligence / Profile preview

propofol + remifentanil + atracurium

Development stage
Unknown
Lead developer
AstraZeneca
Modality
Small Molecules
Administration
Intravenous
01

Overview

A combination of **propofol**, **remifentanil**, and **atracurium** used for induction and maintenance of general anesthesia, especially in surgeries or procedures where rapid onset, profound analgesia, muscle relaxation, and rapid recovery are desired. **Propofol** is an intravenous hypnotic agent facilitating loss of consciousness; **remifentanil** is a potent, ultra-short acting opioid analgesic providing pain relief and blunting responses to surgical stimuli; **atracurium** is a non-depolarizing neuromuscular blocker producing skeletal muscle relaxation, aiding procedures such as intubation and mechanical ventilation. The combination allows lower doses of each component, potentially reducing side effects while providing synergistic anesthetic and analgesic effects. This regimen is commonly used in operating rooms and intensive care settings for its safety, efficacy, and rapid recovery profile[1][3][4][5][8].

Other names
Anesthesia maintenance
02

Targets

MOR (Mu opioid receptor)GABRA1 (Gamma-aminobutyric acid type A receptor alpha 1 subunit)Muscle-type nicotinic acetylcholine receptor

Beyond the preview

Go deeper on propofol + remifentanil + atracurium.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on propofol + remifentanil + atracurium.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call